LSD1-blocking compounds are known to differentially target pluripotent cancer cells including teratocarcinoma, embryonic carcinoma, and seminoma, or embryonic stem cells that express SOX2, while having minimal growth-inhibitory effects on non-pluripotent cancer or normal somatic cells [15, 16, 23]. This evidence concerns the gene SOX2 and teratocarcinoma.